Status:
COMPLETED
Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia
Lead Sponsor:
Mohamed Abd Elmoniem Mohamed
Collaborating Sponsors:
Marwa Salah Abdelrazek Ghanem
Mohammad Khairy El-Badrawy
Conditions:
Bronchoalveolar Lavage
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronaviruses such as SARS-CoV2, MERS-CoV, and SARS-CoV can cause significant morbidity and mortality in infected persons. Lung is the most common site of infection for these viruses, which may manife...
Detailed Description
On December 31, 2019, a cluster of cases of pneumonia in people who were later linked to Wuhan Seafood Market in Wuhan, Hubei, China, were reported. Just a week later, Chinese health authorities confi...
Eligibility Criteria
Inclusion
- Patients with persistent pulmonary infiltrate one month after discharge from isolation building at Mansoura university hospitals, previously tested positive for SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab during admission, discharged and discontinued transmission based precautions according to CDC guidance:
- Symptom-Based Strategy for Discontinuing Transmission-Based Precautions (CDC, 2020)
- Patients with mild to moderate illness who are not severely immunocompromised:
- At least 10 days have passed since symptoms first appeared and
- At least 24 hours have passed since last fever without the use of fever-reducing medications and
- Symptoms (e.g., cough, shortness of breath) have improved
- Patients with severe to critical illness or who are severely immunocompromised1:
- At least 10 days and up to 20 days have passed since symptoms first appeared and
- At least 24 hours have passed since last fever without the use of fever-reducing medications and
- Symptoms (e.g., cough, shortness of breath) have improved
- Consider consultation with infection control experts
Exclusion
- Age: patients less than 18 years old.
- Patient refuse to undergo bronchoscopy.
- Patients unfit for bronchoscopy (hemodynamic instability, recent myocardial infarction, severe hypoxia, uncooperative patient, severe bleeding disorder).
- Patients known to have chronic airway pulmonary diseases or interstitial lung diseases
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06022198
Start Date
January 1 2021
End Date
January 1 2023
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed AbdElmoniem
Al Mansurah, Egypt, 35516